Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy

Frontiers in Endocrinology

Volumn 3, Issue JAN, 2013, Pages

  Gu, Harvest F ^a   Ma, Jun ^b   Gu, Karolin T ^c   Brismar, Kerstin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Viktor Rydberg School Foundation   (Sweden)

Author keywords

Diabetic nephropathy; End stage renal disease; Intercellular adhesion molecule 1; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

EID: 84874229296     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00179     Document Type: Review

References (66)

1. Adeyemo, A. A., Johnson, T., Acheam-pong, J., Oli, J., Okafor, G., Amoah, A., et al. (2005). A genome wide quantitative trait linkage analysis for serum lipids in type 2 diabetes in an African population. Atherosclerosis 181,389-397.
2. Alberti, K. G., and Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of aWHO consultation. Diabet Med. 15, 539-553.
3. Arnold, K., Bordoli, L., Kopp, J., and Schwede, T. (2006). The SWISS-MODEL Workspace: a web-based environment for protein structure homology modelling. Bioinformatks 22,195-201.
4. Arya, R., Demerath, E., Jenkinson, C. P., Goring, H. H., Puppala, S., Farook, V., et al. (2006). quantitative trait locus (QTL) on chromosome 6q influences birth weight in two independent family studies. Hum. Mol Genet. 15, 1569-1579.
5. Ashcroft, F. M., and Rorsman, P. (2012). Diabetes mellitus and the β cell: the last ten years. Cell 148, 1160-1171.
6. Astrup, A. S., Tarnow, L., Pietraszek, L., Schalkwijk, C. G., Stehouwer, C. D., Parving, H. H., et al. (2008). Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 31, 1170-1176.
7. Bonow, R. O., and Gheorghiade, M. (2004). The diabetes epidemic: a national and global crisis. Am. J. Med. 116(Suppl. 5A),2S-10S.
8. Caveney, E. J., and Cohen, O. J. (2011). Diabetes and biomarkers. J. Diabetes Sci. Technol. 5,192-197.
9. Concannon, P., Chen, W M., Julier, C, Morahan, G., Akolkar, B., Erlich, H. A., et al. (2009). Type 1 Diabetes Genetics Consortium. Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes 58, 1018-1022.
10. Cornell, S., and Dorsey, V. J. (2012). Diabetes pharmacotherapy in 2012: considerations in medication selection. Postgrad. Med. 2012 124, 84-94.
11. Gonzalez-Bulnes, A., and Ovilo, C. (2012). Genetic basis, nutritional challenges and adaptive responses in the prenatal origin of obesity and type-2 diabetes. Curr. Diabetes Rev. 8, 144-154.
12. Gong, A. Y., Hu, G., Zhou, R., Liu, J., Feng, Y., Soukup, G. A., et al. (2011). MicroRNA-221 controls expression of intercellular adhesion molecule-1 in epithelial cells in response to Cryp-tosporidium parvum infection. Int. J. Parasitol. 41, 397-403.
13. Guja, C, Todd, J. A., Welsh, K., Marshall, S., and Ionescu-Tirgoviste, C. (1999). Increased transmission of intercellular adhesion-molecule 1, 469E allele in type 1 Romanian diabetic families. Diabetologia 42, 327.
14. Gulcher, J. (2012). Microsatellite markers for linkage and association studies. Cold Spring Harb. Protoc. 2012, 425-432.
15. Heerspink, H. J., and de Zeeuw, D. (2011). The kidney in type 2 diabetes therapy. Rev. Diabet. Stud. 8, 392-402.
16. Hellebrekers, D. M., Castermans, K., Vire, E., Dings, R. P., Hoebers, N. T., Mayo, K. H., et al. (2006). Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 66, 10770-10777.
17. Hellemons, M. E., Kerschbaum, J., Bakker, S. J., Neuwirt, H., Mayer, B., Mayer, G., et al. (2012). Validity of biomarkers predicting onset or progression of nephropathy in patients with type 2 diabetes: a systematic review. Diabet. Med. 29, 567-577.
18. Howell, W. M., Jobs, M., Gyllensten, U., and Brookes, A. J. (1999). Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms. Nat. Biotechnol 17, 87-88.
19. Imperatore, G., Knowler, W. C, Pet-titt, D. J., Kobes, S., Fuller, J. H., Bennett, P. H., et al. (2000). A locus influencing total serum cholesterol on chromosome 19p: results from an autosomal genomic scan of serum lipid concentrations in Pima Indians. Arterioscler. Thromb. Vase. Biol. 20, 2651-2656.
20. Janeway, C. A. Jr. (2001). How the immune system works to protect the host from infection: a personal view. Proc. Natl. Acad. Sci. U.S.A 98, 7461-7468.
21. Kamiuchi, K., Hasegawa, G., Obayashi, H., Kitamura, A., Ishii, M., Yano, M., et al. (2002). Intercellular adhesion molecule-1 (ICAM-1) polymorphism is associated with diabetic retinopathy in type 2 diabetes mellitus. Diabet. Med. 19, 371-376.
22. Kathiresan, S., Melander, O., Guiducci, C, Surti, A., Burtt, N. P., Rieder, M. J., et al. (2008). Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglyc-erides in humans. Nat. Genet. 40, 189-197.
23. Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., et al. (2011). Glucagon-like pep tide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54, 965-978.
24. Kosugi, T., Nakayama, T., Heinig, M., Zhang, L., Yuzawa, Y, Sanchez-Lozada, L. G., et al. (2009). Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am. I Physiol. Renal Physiol. 297, F481-F488.
25. Kraja, A. T., Huang, P., Tang, W, Hunt, S. C, North, K. E., Lewis, C. E., et al. (2008). QTLs of factors of the metabolic syndrome and echocardio-graphic phenotypes: the hypertension genetic epidemiology network study. BMC Med. Genet. 9:103. doi: 10.1186/1471-2350-9-103
26. Lam, D. W., and LeRoith, D. (2012). The worldwide diabetes epidemic. Curr. Opin. Endocrinol. Diabetes Obes. 19, 93-96.
27. Leon, J. M., Freedman, B. I., Miller, M. B., North, K. E., Hunt, S. C, Eckfeldt, J. H., et al. (2007). Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol. Dial. Transplant. 22, 763-771.
28. Lightfoot, Y L., Chen, J., and Mathews, C. E. (2012). Immune-mediated β-cell death in type 1 diabetes: lessons from human β-cell lines. Eur. J. Clin. Invest. 42,1244-1251.
29. Lin, J., Glynn, R. J., Rifai, N., Man-son, J. E., Ridker, P. M., Nathan, D. M., et al. (2008). Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care 31, 2338-2343.
30. Liu, L., Yu, Q., Wang, H., Zhang, S. X., Huang, C, and Chen, X. (2006). Association of intercellular adhesion molecule 1 polymorphisms with retinopathy in Chinese patients with type 2 diabetes. Diabet. Med. 23, 643-648.
31. Liu, W., Zhang, X., Liu, P., Shen, X., Lan, T., Li, W., et al. (2010). Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. Eur. J. Pharmacol. 638, 150-155.
32. Ma, J., Mollsten, A., Prazny, M., Fal-hammar, H., Brismar, K., Dahlquist, G., et al. (2006). Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of type 1 diabetes and diabetic nephropathy. Diabet. Med. 23,1093-1099.
33. Ma, J., Zhang, D., Brismar, K., Efendic, S., and Gu, H. E (2008). Evaluation of the association between the common E469K polymorphism in the ICAM-1 gene and diabetic nephropathy among type 1 diabetic patients in GoKinD population. BMC Med. Genet. 9:47. doi: 10.1186/1471-2350-9-47.
34. Malhotra, A., and Wolford, J. K. (2005). American Diabetes Association GEN-NID Study Group. Analysis of quantitative lipid traits in the genetics of NIDDM (GENNID) study. Diabetes 54,3007-3014.
35. Marshall, S. M. (2004). Recent advances in diabetic nephropathy. Postgrad. Med. J. 80, 624-633.
36. Marshall, S. M. (2012). Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia 55, 2301-2306.
37. Mastej, K., and Adamiec, R. (2008). Neutrophil surface expression of CD lib and CD62L in diabetic microangiopathy. Acta Diabetol. 45, 183-190.
38. Matsui, T., Yamagishi, S., Takeuchi, M., Ueda, S., Fukami, K., and Okuda, S. (2010). Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation. Biochem. Biophys. Res. Commun. 398,326-330.
39. Mein, C. A., Esposito, L., Dunn, M. G., Johnson, G. C, Timms, A. E., Goy, J. V., et al. (1998). A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nat. Genet. 19,297-300.
40. Morahan, G. (2012). Insights into type 1 diabetes provided by genetic analyses. Curr. Opin. Endocrinol. Diabetes Obes. 19,263-270.
41. Mueller, P. W., Rogus, J. J., Cleary, P. A., Zhao, Y, Smiles, A. M., Steffes, M. W., et al. (2006). Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J. Am. Soc. Nephrol. 17, 1782-1790.
42. Nejentsev, S., Guja, C, McCormack, R., Cooper, J., Howson, J. M., Nut-land, S., et al. (2003). Association of intercellular adhesion molecule-1 gene with type 1 diabetes. Lancet 362, 1723-1724.
43. Nejentsev, S., Laine, A. P., Simell, O., and Ilonen, J. (2000). Intercellular adhesion molecule-1 (ICAM-1) K469E polymorphism: no association with type 1 diabetes among Finns. Tissue Antigens 55,568-570.
44. Newman, P. J., Berndt, M. C, Gorski, J., White, G. C. II, Lyman, S., Paddock, C, et al. (1990). PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglob-ulin gene superfamily. Science 247, 1219-1222.
45. Nishimura, M., Obayashi, H., Maruya, E., Ohta, M., Tegoshi, H., Fukui, M., et al. (2000). Association between type 1 diabetes age-at-onset and intercellular adhesion molecule-1(ICAM-1) gene polymorphism. Hum. Immunol. 61, 507-510.
46. Peitsch, M. C. (1995). Protein modeling by E-mail. Biotechnology 13,658-660.
47. Petrovic, M. G., Osredkar, J., Saraga-Babic, M., and Petrovic, D. (2008). K469E polymorphism of the intra-cellular adhesion molecule 1 gene is associated with proliferative diabetic retinopathy in Caucasians with type 2diabetes. Clin. Exp. Ophthalmol. 36, 468-472.
48. Pitkaniemi, J., Moltchanova, E., Haa-pala, L., Harjutsalo, V., Tuomilehto, J., and Hakulinen, T. (2007). Genetic random effects model for family data with long-term survivors: analysis of diabetic nephropathy in type 1 diabetes. Genet. Epidemiol. 31, 697-708.
49. Pollin, T. I., Hsueh, W. C, Steinle, N. I., Snitker, S., Shuldiner, A. R., and Mitchell, B. D. (2004). A genome-wide scan of serum lipid levels in the Old Order Amish. Atherosclerosis 173, 89-96.
50. Qian, Y, Li, S., Ye, S., Chen, Y., Zhai, Z., Chen, K., et al. (2008). Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats. J. Endocrinol. Invest. 31, 1069-1074.
51. Roebuck, K. A., and Finnegan, A. (1999). Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J. Leukoc. Biol. 66, 876-888.
52. Ronaghi, M., Uhlen, M., and Nyren, P. (1998). A sequencing method based on real-time pyrophosphate. Science 281,363-365.
53. Rubio-Guerra, A. E, Vargas-Robles, H., Ayala, G. V., and Escalante-Acosta, B. A. (2007). Correlation between circulating adhesion molecule levels and albuminuria in type 2 diabetic nor-motensive patients. Med. Sci. Monit. 13, CR349-CR352.
54. Sahakyan, K., Klein, B. E., Lee, K. E., Tsai, M. Y, and Klein, R. (2010a). Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus. Eur. I Endocrinol. 162, 1101-1105.
55. Sahakyan, K., Klein, B. E., Myers, C. E., Tsai, M. Y, and Klein, R. (2010b). Novel risk factors in long-term hypertension incidence in type 1 diabetes mellitus. Am. Heart J. 159, 1074-1080.
56. Satko, S. G., Freedman, B. I., and Moos-savi, S. (2005). Genetic factors in end-stage renal disease. Kidney Int. Suppl. 94, S46-S49.
57. Shaw, C. J., and Lupski, J. R. (2004). Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Hum. Mot Genet. 13, R57-R64.
58. Shields, J., and Maxwell, A. P. (2010). Managing diabetic nephropathy. Clin. Med. 10, 500-504.
59. Thomas, M. C, and Groop, P. H. (2011). New approaches to the treatment of nephropathy in diabetes. Expert. Opin. Investig. Drugs 20, 1057-1071.
60. Venter, J. C, Adams, M. D., Myers, E. W, Li, P. W., Mural, R. J., Sutton, G. G., et al. (2001). The sequence of the human genome. Science 291, 1304-1351.
61. Vinita, K., Sripriya, S., Prathiba, K., Vaitheeswaran, K., Sathyabaarathi, R., Rajesh, M., et al. (2012). SNDREAMS project. ICAM-1 K469E polymorphism is a genetic determinant for the clinical risk factors of T2D subjects with retinopathy in Indians: a population-based case-control study. BMJ Open 2, pii: e001036.
62. van de Stolpe, A., and van der Saag, P. T. (1996). Intercellular adhesion molecule-1. J. Mol. Med. (Bert) 74, 13-33.
63. Watanabe, N., Shikata, K., Shikata, Y, Sarai, K., Omori, K., Kodera, R., et al. (2011). Involvement of MAPKs in ICAM-1 expression in glomeru-lar endothelial cells in diabetic nephropathy. Acta Med. Okayama 65, 247-257.
64. Weil, E. J., Curtis, J. M., Hanson, R. L., Knowler, W. C, and Nelson, R. G. (2010). The impact of disadvantage on the development and progression of diabetic kidney disease. Clin. Nephrol. 74(Suppl. 1), S32-S8.
65. Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053.
66. Yokoyama, H., Tahara, H., Emoto, M., Fujiwara, S., Araki, T., Shino-hara, K., et al. (2005). The K469E polymorphism of the intercellular adhesion molecule-1 gene is associated with plasma fibrinogen level in type 2 diabetes. Metabolism 54, 381-386.